Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression
- PMID: 20668043
- PMCID: PMC5393383
- DOI: 10.1210/jc.2010-0441
Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression
Abstract
Context: The typically indolent behavior of pituitary tumors is juxtaposed with high rates of tumor cell invasion into adjacent dural structures, and occasional aggressive behavior. Although clinically significant invasion and malignant transformation remain uncommon, there are limited treatment options available for the management of these aggressive tumors. Recently, case reports have described efficacy of temozolomide for the treatment of aggressive pituitary tumors.
Design: Seven patients with aggressive pituitary tumors have been treated with temozolomide. We compared O(6)-methylguanine methyltransferase (MGMT) promoter methylation and MGMT expression in 14 surgical specimens from these seven patients and correlated these molecular features with the clinical response to temozolomide.
Results: Significant tumor regression was seen in two patients (29%), a 20% reduction in tumor volume with subsequent stable tumor size was noted in one patient, arrest of tumor growth occurred in three patients, and progressive metastatic disease developed during treatment in one patient. The DNA promoter site for MGMT was unmethylated in all 14 adequate specimens, and variable MGMT expression was seen in all 14 cases. There was no correlation between MGMT expression and clinical outcomes.
Conclusions: We conclude that medical therapy with temozolomide can be helpful in the management of life-threatening pituitary tumors that have failed to respond to conventional treatments. The optimal duration of treatment in patients with stabilization or reduction of tumor size has not been established, and long-term follow up studies are needed.
Figures
![F<sc>ig</sc>. 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5393383/bin/zeg0111076170001.gif)
![F<sc>ig</sc>. 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5393383/bin/zeg0111076170002.gif)
![F<sc>ig</sc>. 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5393383/bin/zeg0111076170003.gif)
![F<sc>ig</sc>. 4.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5393383/bin/zeg0111076170004.gif)
Similar articles
-
The role of temozolomide in the treatment of aggressive pituitary tumors.J Clin Neurosci. 2015 Jun;22(6):923-9. doi: 10.1016/j.jocn.2014.12.007. Epub 2015 Mar 12. J Clin Neurosci. 2015. PMID: 25772801 Review.
-
MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas.J Neurooncol. 2011 Sep;104(3):647-57. doi: 10.1007/s11060-011-0532-6. Epub 2011 Feb 11. J Neurooncol. 2011. PMID: 21311951
-
O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.Neurosurgery. 2010 Dec;67(6):1681-91. doi: 10.1227/NEU.0b013e3181f743f5. Neurosurgery. 2010. PMID: 21107199 Review.
-
Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.J Clin Endocrinol Metab. 2010 Oct;95(10):4592-9. doi: 10.1210/jc.2010-0644. Epub 2010 Jul 21. J Clin Endocrinol Metab. 2010. PMID: 20660056
-
Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.Clin Endocrinol (Oxf). 2009 Aug;71(2):226-33. doi: 10.1111/j.1365-2265.2008.03487.x. Epub 2008 Dec 3. Clin Endocrinol (Oxf). 2009. PMID: 19067722
Cited by
-
Metastatic pituitary tumors: an institutional case series.Pituitary. 2023 Oct;26(5):561-572. doi: 10.1007/s11102-023-01341-4. Epub 2023 Jul 31. Pituitary. 2023. PMID: 37523025
-
Refractory Pit1 plurihormonal tumours and thyrotroph adenomas.Pituitary. 2023 Apr;26(2):182-186. doi: 10.1007/s11102-023-01312-9. Epub 2023 Apr 29. Pituitary. 2023. PMID: 37117845 Free PMC article. Review.
-
High-risk pituitary adenomas and strategies for predicting response to treatment.Hormones (Athens). 2022 Mar;21(1):1-14. doi: 10.1007/s42000-021-00333-y. Epub 2022 Jan 21. Hormones (Athens). 2022. PMID: 35061210 Review.
-
Treatment of Aggressive Pituitary Adenomas: A Case-Based Narrative Review.Front Endocrinol (Lausanne). 2021 Nov 15;12:725014. doi: 10.3389/fendo.2021.725014. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34867776 Free PMC article. Review.
-
Aggressive pituitary neuroendocrine tumors: current practices, controversies, and perspectives, on behalf of the EANS skull base section.Acta Neurochir (Wien). 2021 Nov;163(11):3131-3142. doi: 10.1007/s00701-021-04953-6. Epub 2021 Aug 8. Acta Neurochir (Wien). 2021. PMID: 34365544 Review.
References
-
- Meij BP, Lopes MB, Ellegala DB, Alden TD, Laws Jr ER 2002. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated by transsphenoidal surgery. J Neurosurg 96:195–208 - PubMed
-
- Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young Jr WF, Lloyd RV, Davis DH, Guthrie BL, Schoene WC 1997. Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79:804–812 - PubMed
-
- Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A 2005. A critical analysis of tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90:4405–4410 - PubMed
-
- Buchfelder M, Weigel D, Droste M, Mann K, Saller B, Brübach K, Stalla GK, Bidlingmaier M, Strasburger CJ 2009. Investigators of German Pegvisomant Observational Study. Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur J Endocrinol 161:27–35 - PubMed
-
- Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA, Klibanski A 2006. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 91:4482–4488 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials